Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

The Translation of Movement From the Equine to Rider With Relevance for Hippotherapy.

Donaldson MC, Holter AM, Neuhoff S, Arnosky JA, Simpson BW, Vernon K, Blob RW, DesJardins JD.

J Equine Vet Sci. 2019 Jun;77:125-131. doi: 10.1016/j.jevs.2019.02.017. Epub 2019 Feb 28.

PMID:
31133306
2.

The Regional-Specific Relative and Absolute Expression of Gut Transporters in Adult Caucasians: A Meta-Analysis.

Harwood MD, Zhang M, Pathak SM, Neuhoff S.

Drug Metab Dispos. 2019 Aug;47(8):854-864. doi: 10.1124/dmd.119.086959. Epub 2019 May 10.

PMID:
31076413
3.

Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions.

Farasyn T, Crowe A, Hatley O, Neuhoff S, Alam K, Kanyo J, Lam TT, Ding K, Yue W.

J Pharm Sci. 2019 Apr 30. pii: S0022-3549(19)30252-7. doi: 10.1016/j.xphs.2019.04.019. [Epub ahead of print]

PMID:
31047942
4.

Proteomic Quantification of Human Blood-Brain Barrier SLC and ABC Transporters in Healthy Individuals and Dementia Patients.

Al-Majdoub ZM, Al Feteisi H, Achour B, Warwood S, Neuhoff S, Rostami-Hodjegan A, Barber J.

Mol Pharm. 2019 Mar 4;16(3):1220-1233. doi: 10.1021/acs.molpharmaceut.8b01189. Epub 2019 Feb 8.

PMID:
30735053
5.
6.

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates.

Tan ML, Zhao P, Zhang L, Ho YF, Varma MVS, Neuhoff S, Nolin TD, Galetin A, Huang SM.

Clin Pharmacol Ther. 2019 Mar;105(3):719-729. doi: 10.1002/cpt.1205. Epub 2018 Oct 26.

PMID:
30074626
7.

PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants.

Emoto C, Johnson TN, Neuhoff S, Hahn D, Vinks AA, Fukuda T.

CPT Pharmacometrics Syst Pharmacol. 2018 Jul;7(7):464-473. doi: 10.1002/psp4.12306. Epub 2018 Jun 19.

8.

Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach.

Ezuruike U, Humphries H, Dickins M, Neuhoff S, Gardner I, Rowland Yeo K.

Clin Pharmacol Ther. 2018 Dec;104(6):1229-1239. doi: 10.1002/cpt.1085. Epub 2018 Apr 27.

9.

Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?

Neuhoff S, Tucker GT.

Br J Clin Pharmacol. 2018 Jul;84(7):1620-1621. doi: 10.1111/bcp.13538. Epub 2018 Feb 21. No abstract available.

10.
11.

Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport.

Pahwa S, Alam K, Crowe A, Farasyn T, Neuhoff S, Hatley O, Ding K, Yue W.

J Pharm Sci. 2017 Aug;106(8):2123-2135. doi: 10.1016/j.xphs.2017.03.022. Epub 2017 Apr 1.

12.

Development of a physiologically based pharmacokinetic model to predict the effects of flavin-containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure.

Zhou W, Humphries H, Neuhoff S, Gardner I, Masson E, Al-Huniti N, Zhou D.

Biopharm Drug Dispos. 2017 Sep;38(6):389-393. doi: 10.1002/bdd.2074. Epub 2017 May 28.

PMID:
28255999
13.

Characterization of Contributing Factors to Variability in Morphine Clearance Through PBPK Modeling Implemented With OCT1 Transporter.

Emoto C, Fukuda T, Johnson TN, Neuhoff S, Sadhasivam S, Vinks AA.

CPT Pharmacometrics Syst Pharmacol. 2017 Feb;6(2):110-119. doi: 10.1002/psp4.12144. Epub 2016 Dec 9.

14.

Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis.

Burt HJ, Riedmaier AE, Harwood MD, Crewe HK, Gill KL, Neuhoff S.

Drug Metab Dispos. 2016 Oct;44(10):1550-61. doi: 10.1124/dmd.116.071183. Epub 2016 Aug 4.

15.
16.
17.

Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions.

Burt HJ, Neuhoff S, Almond L, Gaohua L, Harwood MD, Jamei M, Rostami-Hodjegan A, Tucker GT, Rowland-Yeo K.

Eur J Pharm Sci. 2016 Jun 10;88:70-82. doi: 10.1016/j.ejps.2016.03.020. Epub 2016 Mar 25.

18.

Breast Cancer Resistance Protein Abundance, but Not mRNA Expression, Correlates With Estrone-3-Sulfate Transport in Caco-2.

Harwood MD, Neuhoff S, Rostami-Hodjegan A, Warhurst G.

J Pharm Sci. 2016 Apr;105(4):1370-5. doi: 10.1016/j.xphs.2016.01.018. Epub 2016 Mar 4.

PMID:
26952881
19.

In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition.

Harwood MD, Achour B, Neuhoff S, Russell MR, Carlson G, Warhurst G, Rostami-Hodjegan A.

Drug Metab Dispos. 2016 Mar;44(3):476-80. doi: 10.1124/dmd.115.067777. Epub 2016 Feb 3.

PMID:
26842595
20.

Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer.

Walsh C, Bonner JJ, Johnson TN, Neuhoff S, Ghazaly EA, Gribben JG, Boddy AV, Veal GJ.

Br J Clin Pharmacol. 2016 May;81(5):989-98. doi: 10.1111/bcp.12878. Epub 2016 Feb 25.

21.

In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-Glycoprotein and Breast Cancer Resistance Protein: Part I: A Cross-Laboratory Comparison of Transporter-Protein Abundances and Relative Expression Factors in Human Intestine and Caco-2 Cells.

Harwood MD, Achour B, Neuhoff S, Russell MR, Carlson G, Warhurst G; Amin Rostami-Hodjegan.

Drug Metab Dispos. 2016 Mar;44(3):297-307. doi: 10.1124/dmd.115.067371. Epub 2015 Dec 2.

PMID:
26631742
22.

Lost in centrifugation: accounting for transporter protein losses in quantitative targeted absolute proteomics.

Harwood MD, Russell MR, Neuhoff S, Warhurst G, Rostami-Hodjegan A.

Drug Metab Dispos. 2014 Oct;42(10):1766-72. doi: 10.1124/dmd.114.058446. Epub 2014 Jul 24.

PMID:
25061159
23.

Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin.

Rose RH, Neuhoff S, Abduljalil K, Chetty M, Rostami-Hodjegan A, Jamei M.

CPT Pharmacometrics Syst Pharmacol. 2014 Jul 9;3:e124. doi: 10.1038/psp.2014.24.

24.

In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects.

Sjögren E, Abrahamsson B, Augustijns P, Becker D, Bolger MB, Brewster M, Brouwers J, Flanagan T, Harwood M, Heinen C, Holm R, Juretschke HP, Kubbinga M, Lindahl A, Lukacova V, Münster U, Neuhoff S, Nguyen MA, Peer Av, Reppas C, Hodjegan AR, Tannergren C, Weitschies W, Wilson C, Zane P, Lennernäs H, Langguth P.

Eur J Pharm Sci. 2014 Jun 16;57:99-151. doi: 10.1016/j.ejps.2014.02.010. Epub 2014 Mar 15. Review.

PMID:
24637348
25.

A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine.

Jamei M, Bajot F, Neuhoff S, Barter Z, Yang J, Rostami-Hodjegan A, Rowland-Yeo K.

Clin Pharmacokinet. 2014 Jan;53(1):73-87. doi: 10.1007/s40262-013-0097-y.

26.

Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux.

Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, Rostami-Hodjegan A.

J Pharm Sci. 2013 Sep;102(9):3145-60. doi: 10.1002/jps.23594. Epub 2013 May 22.

PMID:
23703021
27.

Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.

Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, Rostami-Hodjegan A.

J Pharm Sci. 2013 Sep;102(9):3161-73. doi: 10.1002/jps.23607. Epub 2013 May 19.

PMID:
23686764
28.

Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions.

Ellens H, Deng S, Coleman J, Bentz J, Taub ME, Ragueneau-Majlessi I, Chung SP, Herédi-Szabó K, Neuhoff S, Palm J, Balimane P, Zhang L, Jamei M, Hanna I, O'Connor M, Bednarczyk D, Forsgard M, Chu X, Funk C, Guo A, Hillgren KM, Li L, Pak AY, Perloff ES, Rajaraman G, Salphati L, Taur JS, Weitz D, Wortelboer HM, Xia CQ, Xiao G, Yamagata T, Lee CA.

Drug Metab Dispos. 2013 Jul;41(7):1367-74. doi: 10.1124/dmd.112.050542. Epub 2013 Apr 25.

29.

Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.

Bentz J, O'Connor MP, Bednarczyk D, Coleman J, Lee C, Palm J, Pak YA, Perloff ES, Reyner E, Balimane P, Brännström M, Chu X, Funk C, Guo A, Hanna I, Herédi-Szabó K, Hillgren K, Li L, Hollnack-Pusch E, Jamei M, Lin X, Mason AK, Neuhoff S, Patel A, Podila L, Plise E, Rajaraman G, Salphati L, Sands E, Taub ME, Taur JS, Weitz D, Wortelboer HM, Xia CQ, Xiao G, Yabut J, Yamagata T, Zhang L, Ellens H.

Drug Metab Dispos. 2013 Jul;41(7):1347-66. doi: 10.1124/dmd.112.050500. Epub 2013 Apr 25.

30.

Comment on the article "physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions".

Neuhoff S, Tucker GT.

Pharm Res. 2013 Jun;30(6):1467-8. doi: 10.1007/s11095-013-0988-5. Epub 2013 Mar 16. No abstract available.

PMID:
23504339
31.

Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption.

Harwood MD, Neuhoff S, Carlson GL, Warhurst G, Rostami-Hodjegan A.

Biopharm Drug Dispos. 2013 Jan;34(1):2-28. doi: 10.1002/bdd.1810. Epub 2012 Oct 8. Review.

PMID:
22927116
32.

Human umbilical cord blood cells restore brain damage induced changes in rat somatosensory cortex.

Geissler M, Dinse HR, Neuhoff S, Kreikemeier K, Meier C.

PLoS One. 2011;6(6):e20194. doi: 10.1371/journal.pone.0020194. Epub 2011 Jun 1.

34.

Population-based mechanistic prediction of oral drug absorption.

Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, Tucker G.

AAPS J. 2009 Jun;11(2):225-37. doi: 10.1208/s12248-009-9099-y. Epub 2009 Apr 21. Review.

35.

Proliferation, differentiation, and cytokine secretion of human umbilical cord blood-derived mononuclear cells in vitro.

Neuhoff S, Moers J, Rieks M, Grunwald T, Jensen A, Dermietzel R, Meier C.

Exp Hematol. 2007 Jul;35(7):1119-31.

PMID:
17588481
36.

Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells.

Meier C, Middelanis J, Wasielewski B, Neuhoff S, Roth-Haerer A, Gantert M, Dinse HR, Dermietzel R, Jensen A.

Pediatr Res. 2006 Feb;59(2):244-9.

PMID:
16439586
37.

Impact of extracellular protein binding on passive and active drug transport across Caco-2 cells.

Neuhoff S, Artursson P, Zamora I, Ungell AL.

Pharm Res. 2006 Feb;23(2):350-9. Epub 2006 Jan 1.

PMID:
16388407
38.

pH-Dependent passive and active transport of acidic drugs across Caco-2 cell monolayers.

Neuhoff S, Ungell AL, Zamora I, Artursson P.

Eur J Pharm Sci. 2005 Jun;25(2-3):211-20. Epub 2005 Mar 23.

PMID:
15911216
39.

Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa(flux) method.

Avdeef A, Artursson P, Neuhoff S, Lazorova L, Gråsjö J, Tavelin S.

Eur J Pharm Sci. 2005 Mar;24(4):333-49. Epub 2005 Jan 20.

PMID:
15734300
40.
41.

Dimeric 4-aryl-1,4-dihydropyridines as novel HIV-1 protease inhibitors--affinities to intestinal P-glycoprotein.

Hilgeroth A, Dressler C, Neuhoff S, Spahn-Langguth H, Langguth P.

Pharmazie. 2000 Oct;55(10):784-5. No abstract available.

PMID:
11082847
42.

Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites.

Neuhoff S, Langguth P, Dressler C, Andersson TB, Regårdh CG, Spahn-Langguth H.

Int J Clin Pharmacol Ther. 2000 Apr;38(4):168-79.

PMID:
10783826
43.

Single dose of azithromycin for the treatment of genital chlamydial infections in adolescents.

Hammerschlag MR, Golden NH, Oh MK, Gelling M, Sturdevant M, Brown PR, Aras Z, Neuhoff S, Dumornay W, Roblin PM.

J Pediatr. 1993 Jun;122(6):961-5.

PMID:
8388950
44.

Pelvic inflammatory disease in adolescents.

Golden N, Neuhoff S, Cohen H.

J Pediatr. 1989 Jan;114(1):138-43.

PMID:
2642549
45.

The use of pelvic ultrasonography in the evaluation of adolescents with pelvic inflammatory disease.

Golden N, Cohen H, Gennari G, Neuhoff S.

Am J Dis Child. 1987 Nov;141(11):1235-8.

PMID:
3314478
46.

Prevalence of Chlamydia trachomatis cervical infection in female adolescents.

Golden N, Hammerschlag M, Neuhoff S, Gleyzer A.

Am J Dis Child. 1984 Jun;138(6):562-4.

PMID:
6720642
47.

False negative oxytocin challenge test result; review.

Neuhoff SD, Gal D, Tancer ML.

N Y State J Med. 1979 Sep;79(10):1537-40. No abstract available.

PMID:
293507
48.

Endometrial carcinoma in previously ovariectomized patients.

Gal D, Neuhoff S, Tancer ML.

Gynecol Oncol. 1979 Aug;8(1):44-8. No abstract available.

PMID:
456935
49.

False negative oxytocin challenge test: report of three cases.

Gal D, Neuhoff S, Lilling MI, Tancer ML.

Am J Obstet Gynecol. 1979 Jan 1;133(1):111-3. No abstract available.

PMID:
760531

Supplemental Content

Loading ...
Support Center